黏液样脂肪肉瘤术前放疗减量:DOREMY 2期非随机临床试验长期随访
DOREMY是一项在欧洲和美国9家肉瘤中心开展的前瞻性单组2期非随机试验,评估活检证实且易位确认的躯干或肢体局限期黏液样脂肪肉瘤患者接受36 Gy术前放疗(每日2 Gy)后手术的长期疗效与毒性。
要点
- 36 Gy术前放疗后5年局部无复发生存率达97.4%。
- 21%患者出现伤口并发症,16%需干预。
- 2级和3级晚期毒性发生率分别为15%和3%。
核心结论
- 减量术前放疗在黏液样脂肪肉瘤中显示极佳局部控制和良好毒性特征。
研究设计与样本
- 前瞻性单组2期非随机临床试验,在欧洲和美国9家三级肉瘤中心开展。
- 干预为术前36 Gy放疗(每日2 Gy)后手术。
主要发现
- 5年局部无复发生存率97.4%(95% CI,93.9%-100%)。
- 5年无进展生存率81.0%(95% CI,72.6%-89.4%)。
- 5年疾病特异性生存率89.5%(95% CI,82.6%-96.4%)。
- 5年总生存率88.5%(95% CI,81.2%-95.8%)。
- 18例(21%)发生伤口并发症,14例(16%)需干预;2级和3级晚期毒性分别见于13例(15%)和3例(3%)。
关键数值与推荐
- 推荐减量术前放疗36 Gy(每日2 Gy)作为黏液样脂肪肉瘤的适当治疗选择,需与患者共同决策。
临床怎么用
- 对于活检证实且易位确认的躯干或肢体局限期黏液样脂肪肉瘤,可考虑36 Gy术前放疗后手术。
- 治疗决策应与患者共同讨论,权衡局部控制获益与伤口并发症及晚期毒性风险。
局限性
- 单组非随机设计,无对照组。
- 罕见肿瘤,开展3期试验不切实际。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prospective data from 2 phase 2 trials showed favorable wound complication rates and promising local control after a reduced preoperative radiotherapy dose for myxoid liposarcoma (MLS). However, long-term follow-up data are currently lacking. OBJECTIVE: To determine the efficacy and toxicity profile of a reduced preoperative radiotherapy dose in patients with MLS with long-term follow-up. DESIGN, SETTING, AND PARTICIPANTS: The Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma (DOREMY) trial is a prospective, single-group, phase 2 nonrandomized clinical trial conducted in 9 tertiary sarcoma centers in Europe and the US. Eligible patients were adults with biopsy-proven and translocation-confirmed localized MLS of the trunk or extremity who were enrolled from November 24, 2010, to May 14, 2020. Data were analyzed from January to December 2025. INTERVENTION: Preoperative radiotherapy to a reduced dose of 36 Gy in once-daily 2-Gy fractions followed by resection. MAIN OUTCOMES AND MEASURES: Long-term local recurrence-free survival, progression-free survival, disease-specific survival, overall survival, and late toxic effects. RESULTS: Ninety patients (mean [SD] age, 47 [13.1] years; 50 [56%] male) were included and followed up for a median (IQR) of 66.4 (48.8-87.5) months. Preoperative radiotherapy was delivered according to protocol in all patients. Surgery was not performed in 3 patients (3%) due to intercurrent metastatic disease. Local recurrence-free survival, progression-free survival, disease-specific survival, and overall survival rates at 5 years were 97.4% (95% CI, 93.9%-100%), 81.0% (95% CI, 72.6%-89.4%), 89.5% (95% CI, 82.6%-96.4%), and 88.5% (95% CI, 81.2%-95.8%), respectively. In total, 18 patients (21%) experienced a wound complication, and 14 (16%) required intervention. Any grade 2 or grade 3 late toxic effects were seen among 13 patients (15%) and 3 patients (3%), respectively. CONCLUSIONS AND RELEVANCE: This long-term analysis of the DOREMY nonrandomized clinical trial demonstrated excellent local control and a favorable toxicity profile following dose reduction of preoperative radiotherapy in patients with MLS. These compelling phase 2 findings support adoption of this regimen as an appropriate treatment option through shared decision-making with the patient, given the impracticality of conducting a phase 3 trial for a rare cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02106312.
引用
- Lansu J, Bovée JVMG, Braam PM, et al. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 42141895. doi:10.1001/jamaoncol.2026.1577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。